- Home
- FCAP vs XFOR Comparison
FCAP vs XFOR Comparison
Compare FCAP & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCAP | XFOR |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.7M | 377.3M |
| IPO Year | 1998 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FCAP | XFOR |
|---|---|---|
| Price | $62.55 | $3.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 10.8K | ★ 674.3K |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 36.97 | N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $7,170,000.00 | $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.25 | ★ N/A |
| Revenue Growth | 1.57 | ★ 150.00 |
| 52 Week Low | $37.64 | $2.80 |
| 52 Week High | $71.00 | $4.83 |
Technical Indicators
Market Signals| Indicator | FCAP | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 30.30 |
| Support Level | $62.07 | $2.94 |
| Resistance Level | $64.20 | $4.40 |
| Average True Range (ATR) | 1.50 | 0.23 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 59.84 | 16.67 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is an Indiana chartered commercial bank that provides a variety of banking services to individuals and businesses. It provides retail and business banking, residential mortgage lending, real estate finance, and asset-based lending. The bank's primary source of revenue is real estate mortgage loans.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.